A Phase I Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC 742460) in Children With Relapsed/Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 Jul 2014
At a glance
- Drugs Cixutumumab (Primary)
- Indications CNS cancer; Ewing's sarcoma; Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 21 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jan 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.